Valve Disease Pearls
Issues in heart valve disease for the primary care provider

John J. Reusch, Jr., MD, FACC
Colorado ACP Meeting
February 3, 2017
Conflict of Interest

• No disclosures
Learning Objectives

Understand the role of the echocardiogram in the management of heart valve disease.

Understand the difference between primary and secondary heart valve disease.

Understand the difference between primary and secondary pulmonary hypertension and the role of echo in pulmonary hypertension.
How Patients present with valve disease

- Murmur
- Symptoms
- Imaging (echo)
- Past Medical History
Heart Murmur – are there patients who don’t need an echo?

- Short answer – No. Echo is a great tool.
- Impressive Murmur? – Intensity, duration, location, consistency
- Active, asymptomatic patient?
- An active, asymptomatic patient with an unimpressive murmur does not require an echo (but they might want one!)
Symptoms of valve disease are nonspecific

- DOE
- Reduced exercise capacity
- CHF symptoms: SOB, orthopnea, PND
- Edema is less specific and often non-cardiac in origin
Echo is only one piece of the data

- Meticulous History and physical
- Presence/absence of symptoms
- Symptoms are usually slowly progressive; patients may be unaware
- ECG
- CXR
- Routine labs
- Echo
Echo in valve disease

- (Etiology and severity of valve lesion)
- But most important:
  - LV size and function
  - RV size and function
  - RV/PA systolic pressure
Primary vs Secondary Heart valve Disease

- The vast majority of valve disease is **secondary** to another condition (MR secondary to LVSD, TR secondary to RVSD/pulmonary disease)
- Treat the underlying condition
Primary Valve Disease

- **Primary** valve disease (AS, AI, MVP with MR, rheumatic MS) has no effective **medical** treatment
- It’s a **mechanical** problem that requires careful f/u, and when appropriate, a mechanical solution
Medical management of valve disease

- CHF – usual Rx
- HTN – usual Rx
- Pulmonary disease
- Obesity/OSA
- (Oral Health)
- (Influenza and pneumococcal vaccinations)
Infectious Endocarditis Prophylaxis (2014 ACC valve disease guideline)

- Prosthetic valves
- Previous endocarditis
- s/p cardiac transplant
  - valve regurgitation
- Congenital heart disease
  - Unrepaired cyanotic defect
  - first 6 months after repair
  - residual defects at or adjacent to the site of a patch or prosthetic device
Infectious Endocarditis Prophylaxis (2014 ACC valve disease guideline)

- Not recommended for non-dental procedures (EGD, colonoscopy, cystoscopy, other surgery, TEE)
- No longer recommended for any other valve lesion (MVP, Bicuspid AV, MR, TR, etc.)
Echo in valve disease
(2014 ACC valve disease guideline)

- Class I: TTE is recommended in the **initial evaluation** of patients with known or suspected VHD to confirm the diagnosis, establish etiology, determine severity, assess hemodynamic consequences, determine prognosis, and evaluate for timing of intervention.

- Class I: TTE is recommended in patients with **known VHD with any change** in symptoms or physical examination findings.

- Class I: **Periodic monitoring** with TTE is recommended in **asymptomatic** patients with **known VHD** at intervals depending on valve lesion, severity, ventricular size, and ventricular function.
Echo estimate of pulmonary artery systolic pressure

- Requires presence of TR – at least a trace
- Measure TR velocity
- Simplified Bernoulli equation: \(4V^2\)
- 3 m/s
- RA pressure – typically assume 5 mmHg
- RV pressure + RA pressure = estimated PA systolic pressure
When can I not worry about Pulmonary Hypertension?

- TR velocity <3.5 m/s
- Estimated PA systolic pressure <50
- Especially when there is a likely explanation
  - (LV dysfunction, pulmonary disease, obesity, OSA)
- Treat the underlying problem
When do I need to care about Pulmonary Hypertension?

- TR velocity >3.5 m/s
- Estimated PA systolic pressure >50
- When there isn’t a likely explanation
- Especially when there is RV enlargement and dysfunction
Primary vs. Secondary Pulmonary Hypertension

- 99% is secondary
- Address the underlying problem:
  - Lung disease
  - Hypoxia
  - Obesity
  - OSA
  - LV dysfunction (systolic, diastolic)
Right-Sided Valve Disease

- Tricuspid and Pulmonic regurgitation are VERY COMMON
- PR is almost never an issue (will not discuss)
- TR is typically a bystander – almost NEVER a PRIMARY clinical problem.
- So TR does not require echo follow-up in and of itself.
- The important issues are:
  - RV (and LV) size and function
  - Pulmonary HTN
  - Pulmonary disease/hypoxia
  - Obesity/OSA
Specific Valve Lesions

Aortic Stenosis
Clinical follow-up of AS

- Most common primary valve disease
- 2 types: Bicuspid AV (age <65), Senile calcific (age >75)
- Hemodynamic progression leading to symptoms occurs in all asymptomatic patients with AS.
- Survival during asymptomatic phase is similar to age-matched controls. Low risk of sudden death (<1% per year)
- Substantial overlap in hemodynamic severity between asymptomatic and symptomatic patients
- No single parameter indicates the need for AVR.
- Combination of symptoms, valve anatomy, and hemodynamics
Clinical follow-up of AS

- Symptoms: DOE, decreased exercise tolerance.
- The classical symptoms of syncope, angina, and HF are late manifestations of disease, most often seen in patients in whom early symptom onset was not recognized and intervention was inappropriately delayed.
- The only effective treatment is surgical or trans catheter AVR (there is no medical therapy).
- Once even mild AS symptoms are present, outcomes are extremely poor unless outflow obstruction is relieved.
TAVR

- **Class I**  TAVR is recommended in patients who meet an indication for AVR who have a prohibitive risk for surgical AVR and a predicted post-TAVR survival greater than 12 months.

- **Class IIa**  TAVR is a reasonable alternative to surgical AVR in patients who meet an indication for AVR and who have high surgical risk for surgical AVR. (age >80)

- **Class III**  TAVR is not recommended in patients in whom existing comorbidities would preclude the expected benefit from correction of AS.
Aortic Regurgitation

- Acute AR: IE, aortic dissection.
- Chronic AR: bicuspid aortic valve, dilation of the ascending aorta or the sinuses of Valsalva, rheumatic heart disease.
- AR is mainly chronic and slowly progressive.
- Vasodilators (dihydropyridine CCB’s, ACE inhibitors/ARBs) may be helpful, but unproven and not recommended routinely.
- In symptomatic patients who are candidates for surgery, medical therapy is not a substitute for AVR.
Bicuspid Aortic Valve

- Most patients with a bicuspid aortic valve will develop AS or AR over their lifetime.
- Ascending aortic aneurysm – frequently associated with BAV
- The echo report should include aortic measurements at the aortic annulus, sinuses, sinotubular junction, and mid-ascending aorta.
- Coarctation of the Aorta – Doppler interrogation of the proximal descending aorta
Bicuspid Aortic Valve

- In 20% to 30% of patients with bicuspid valves, other family members also have bicuspid valve disease and/or an associated aortopathy.
- A specific genetic cause has not been identified, and the patterns of inheritance are variable.
- Important to take a family history and inform patients that other family members may be affected.
- Many valve experts recommend screening all first-degree relatives of patients with bicuspid aortic valve. Insufficient data to know whether this is appropriate.
BAV – Aortic Aneurysm

- Serial evaluation of the ascending aorta by echo, CMR, or CT angiography is recommended in patients with BAV and an aortic diameter greater than 4.0 cm.

- Examination interval determined by the degree and rate of progression of aortic dilation and by family history.

- Aortic diameter greater than 4.5 cm – evaluation should be performed annually.

- No proven drug therapies to reduce the rate of progression of aortic dilation. BB often used/recommended.
Class I  Operative repair of the ascending aorta is indicated in patients with BAV when ascending aorta is greater than 5.5 cm. (Level of Evidence: B)

Previous guidelines have recommended surgery when the degree of aortic dilation is >5.0 cm – evidence supporting these previous recommendations was limited and anecdotal.

Surgery is recommended with aortic dilation of 5.1 cm to 5.5 cm only if there is a family history of aortic dissection or rapid progression of dilation.

BSA can be considered in decision-making.
Mitral stenosis

- Class I: TTE is indicated in patients with signs or symptoms of MS to establish the diagnosis, quantify hemodynamic severity (mean pressure gradient, mitral valve area, and pulmonary artery pressure), assess concomitant valvular lesions, and demonstrate valve morphology (to determine suitability for mitral commissurotomy). (Level of Evidence: B)

- Class I: TEE should be performed in patients who are being considered for percutaneous mitral balloon commissurotomy to assess the presence or absence of left atrial thrombus and to further evaluate the severity of MR. (Level of Evidence: B)
Balloon Commissurotomy

<table>
<thead>
<tr>
<th>Score</th>
<th>Leaflet mobility</th>
<th>Valve thickness</th>
<th>Subvalvular thickening</th>
<th>Valvular calcification</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Highly mobile with little restriction</td>
<td>Normal thickness (4-5mm)</td>
<td>Minimal chordal thickening</td>
<td>A single area of calcification</td>
</tr>
<tr>
<td>2</td>
<td>Decreased mobility in midportion and base of leaflets</td>
<td>Midleaflet/marginal thickening</td>
<td>Chordal thickening 1/3 up chordal length</td>
<td>Confined to leaflet margins</td>
</tr>
<tr>
<td>3</td>
<td>Forward movement of valve leaflets in diastole</td>
<td>Total leaflet thickening (5-8mm)</td>
<td>Chordal thickening 2/3 up chordal length</td>
<td>Up to mid-leaflet</td>
</tr>
<tr>
<td>4</td>
<td>No or minimal forward movement of leaflets in diastole</td>
<td>Severe thickening (≥8mm)</td>
<td>Complete chordal thickening to papillary muscle</td>
<td>Throughout most of the valve leaflets</td>
</tr>
</tbody>
</table>
Secondary Mitral Regurgitation

- Far and away the most common cause of MR
- This issue is not the valve, the issue is CHF, LV systolic dysfunction.
- Treat the CHF!
- Interventions on the valve to address MR/CHF have largely been unsuccessful
- Echo can be done as needed to manage CHF (decisions about ICD and Bi-V pacing, assessing prognosis, aggressiveness of medical Rx)
- There is little reason to do f/u echo for the MR.
Primary Mitral Regurgitation

- Trace, mild MR does not need f/u echo.
- > Moderate MR does require f/u echo
- Moderate MR with normal LV size/function and no symptoms – if stable over a few years can be followed more loosely
- > Moderate MR needs more close f/u – approximately annually.
- Bottom line – LV size and function: if severe MR, enlarging LV, and falling LVEF, cardiology consultation for MVR
- Symptoms can be quite clear or quite tricky